• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Harmony Biosciences Holdings Inc.

    4/3/26 8:05:05 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HRMY alert in real time by email
    DEFA14A 1 hrmy-20260403xdefa14a.htm DEFA14A

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ​


    ​

    SCHEDULE 14A

    PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE

    SECURITIES EXCHANGE ACT OF 1934

    ​


    ​

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    ​

    Check the appropriate box:

    ​

    ☐Preliminary Proxy Statement

    ​

    ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ​

    ☐Definitive Proxy Statement

    ​

    ☒Definitive Additional Materials

    ​

    ☐Soliciting Material Pursuant to  ☐ 240.14a-11(c) or  ☐ 240.14a-2

    ​

    Harmony Biosciences Holdings, Inc.

    (Name of Registrant as Specified In Its Charter)

    ​

    Payment of Filing Fee (Check the appropriate box):

    ​

    ☒No fee required.

    ​

    ☐Fee paid previously with preliminary materials.

    ​

    ☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

    ​


    GRAPHIC

    Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V89931-P48489 HARMONY BIOSCIENCES HOLDINGS, INC. 630 WEST GERMANTOWN PIKE, SUITE 215 PLYMOUTH MEETING, PA 19462 HARMONY BIOSCIENCES HOLDINGS, INC. You invested in HARMONY BIOSCIENCES HOLDINGS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on May 14, 2026. Vote Virtually at the Meeting* May 14, 2026 1:00 p.m. Eastern Time Virtually at: www.virtualshareholdermeeting.com/HRMY2026 *Please check the meeting materials for any special requirements for meeting attendance. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to April 30, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. 2026 Annual Meeting Vote by May 13, 2026 11:59 PM ET

    GRAPHIC

    Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V89932-P48489 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. 1. The election of four Class III directors to serve until our 2029 annual meeting of stockholders and until their successors are duly elected and qualified. For Nominees: 01) Geno J. Germano 02) Troy Ignelzi 03) Ron Philip 04) Andreas Wicki, Ph.D. 2. Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026. For 3. Non-binding, advisory vote on the compensation of our named executive officers pursuant to the SEC’s compensation disclosure rules. For NOTE: To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.

    Get the next $HRMY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HRMY

    DatePrice TargetRatingAnalyst
    2/23/2026Buy → Hold
    Deutsche Bank
    2/23/2026Buy → Hold
    Truist
    2/11/2026$46.00Neutral
    UBS
    7/21/2025$48.00Buy
    Truist
    7/10/2025$33.00Neutral
    Goldman
    6/2/2025$61.00Outperform
    Oppenheimer
    2/11/2025$55.00Buy
    Deutsche Bank
    12/17/2024$75.00Buy
    H.C. Wainwright
    More analyst ratings

    $HRMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Harmony Biosciences downgraded by Deutsche Bank

    Deutsche Bank downgraded Harmony Biosciences from Buy to Hold

    2/23/26 8:31:47 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences downgraded by Truist

    Truist downgraded Harmony Biosciences from Buy to Hold

    2/23/26 8:31:36 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS resumed coverage on Harmony Biosciences with a new price target

    UBS resumed coverage of Harmony Biosciences with a rating of Neutral and set a new price target of $46.00

    2/11/26 7:39:03 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board

    Appointments support Harmony's next phase of growth and long‑term value creation Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and updates to its Board of Directors, including the appointment of Troy Ignelzi as a director and the nomination of Geno J. Germano as a director for election at Harmony's 2026 Annual Meeting of Shareholders. Mr. Anastasiou previously served on Harmony Biosciences' Board of Directors, where he contributed strategic insight across the business during a period of continued growth and operational evolution. He brings more than three decades of experience building and leading biotechn

    4/2/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that Harmony's management team will participate in a fireside chat at the upcoming 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026, at 9:30 a.m. ET. A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Har

    3/31/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences to Participate in Upcoming Investor Conferences

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that Harmony's management team will attend the following upcoming investor conferences. Leerink Partners Global Healthcare Conference Date: March 9, 2026 Location: Miami, FL UBS Biotech Summit Date: March 9, 2026 Location: Miami, FL Barclays 28th Annual Global Healthcare Conference Date: March 10, 2026 Location: Miami, FL About Harmony Biosciences Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to

    3/4/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    SEC Filings

    View All

    SEC Form DEFA14A filed by Harmony Biosciences Holdings Inc.

    DEFA14A - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)

    4/3/26 8:05:05 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Harmony Biosciences Holdings Inc.

    DEF 14A - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)

    4/3/26 8:00:16 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)

    4/2/26 8:15:09 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Kapadia Sandip sold $139,171 worth of shares (3,746 units at $37.15), decreasing direct ownership by 13% to 24,521 units (SEC Form 4)

    4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)

    1/28/26 8:19:26 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER Kapadia Sandip converted options into 8,538 shares and covered exercise/tax liability with 4,792 shares (SEC Form 4)

    4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)

    1/26/26 4:49:02 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF STRATEGY OFFICER Serafin Andrew converted options into 5,100 shares and covered exercise/tax liability with 2,242 shares (SEC Form 4)

    4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)

    1/26/26 4:48:00 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Leadership Updates

    Live Leadership Updates

    View All

    Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board

    Appointments support Harmony's next phase of growth and long‑term value creation Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and updates to its Board of Directors, including the appointment of Troy Ignelzi as a director and the nomination of Geno J. Germano as a director for election at Harmony's 2026 Annual Meeting of Shareholders. Mr. Anastasiou previously served on Harmony Biosciences' Board of Directors, where he contributed strategic insight across the business during a period of continued growth and operational evolution. He brings more than three decades of experience building and leading biotechn

    4/2/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Ron Philip to the Company's Board of Directors. Ron Philip is the President and Chief Executive Officer of Orbital Therapeutics. Ron has 30 years of experience building companies, leading organizational growth, and guiding teams through the development, regulatory approval, and commercialization of novel therapies. Prior to Orbital, he was Chief Executive Officer of Spark Therapeutics, where he led the commercial launch of a novel gene therapy to treat an inherited form of blindness, expanded its therapeutic platform to larger disease areas, and acquired new technologies and assets through business developm

    4/3/25 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced the appointment of Adam Zaeske as Executive Vice President and Chief Commercial Officer (CCO), effective March 31, 2025. The company's current CCO, Jeffrey Dierks, is voluntarily stepping down for personal reasons. Zaeske brings 25 years of global leadership across the pharmaceutical industry, building teams and transforming organizations in both the U.S. and Europe. He has broad functional experience spanning commercial strategy and operations, sales, marketing, market access, new product planning and finance. At Harmony, Zaeske will be responsible for leading the company's commercial organization, setting commercial strate

    3/24/25 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Financials

    Live finance-specific insights

    View All

    Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

    WAKIX 2025 Net Revenue of $868.5 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in Narcolepsy Recently Completed Settlements with 3 Additional Generic Filers Toward Goal of Securing WAKIX Franchise Pitolisant GR NDA Submission on Track for Q2 2026; Extends the Pitolisant Franchise into the 2040s Exploring New Opportunities to Broaden the Pitolisant Franchise Beyond Orphan/Rare into Larger CNS Indications Potential Best-In-Class Orexin-2 Agonist (BP1.15205) Phase 1 Trial Ongoing; Clinical Data Expected in Mid-2026 Conference Call and Webcast Today at 8:30 a.m. ET Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced ear

    2/24/26 7:30:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on February 24, 2026, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-274-7083 (domestic) or 203-518-9786 (international), and reference passcode HRMYQ425. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Har

    2/10/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M

    WAKIX® (pitolisant) Franchise Delivers Net Revenue of $239M in Q3 2025 (+29% YoY Growth) Record Increase in Average Number of Patients of Approximately 500 to Achieve 8,100 Average Patients in Q3 2025 Strong Cash Generation of $106M with $778M On Balance Sheet at end of Q3 2025 Pitolisant HD IND submitted; On Track to Initiate Phase 3 Trials in Narcolepsy and Idiopathic Hypersomnia in Q4 2025 Potential Best-In-Class Orexin 2 Agonist (BP1.15205) On Track to Dose First Subject in Q4 2025; Phase 1 Clinical Data in 2026 Late-Stage Catalyst-Rich Pipeline Advances with up to Five Phase 3 Programs by Year End Conference Call and Webcast Today at 8:30 a.m. ET Harmony Biosciences Holdings, In

    11/4/25 7:30:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

    SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    2/13/24 7:06:51 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

    SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    2/13/24 5:06:22 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

    SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    2/9/24 9:03:03 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care